ErbB‐4 may control behavior of prostate cancer cells and serve as a target for molecular therapy

To assess ErbB‐4 expression in advanced human prostate cancer (PC) cell lines, the role of ErbB‐4 in motility, migration, and proliferative/tumorigenic potential of PC cells, and efficacy of anti‐ErbB‐4 monoclonal antibody (Mab) treatment on PC cells in vitro and tumor growth in vivo.

[1]  J. Bartlett,et al.  The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer , 2006, Clinical Cancer Research.

[2]  A. Fasolo,et al.  ErbB4 Expression in Neural Progenitor Cells (ST14A) Is Necessary to Mediate Neuregulin-1β1-induced Migration* , 2004, Journal of Biological Chemistry.

[3]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[4]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[5]  Y. Yarden,et al.  Oncogenic growth factor receptors: implications for signal transduction therapy. , 2004, Seminars in cancer biology.

[6]  T. Giordano,et al.  Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma , 2004, Cancer Research.

[7]  S. Carroll,et al.  Constitutive Activation of the Neuregulin-1/erbB Signaling Pathway Promotes the Proliferation of a Human Peripheral Neuroepithelioma Cell Line , 2004, Journal of Neuro-Oncology.

[8]  S. Fosså,et al.  Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence , 2004, British Journal of Cancer.

[9]  W. Gullick.  c‐erbB‐4/HER4: friend or foe? , 2003, The Journal of pathology.

[10]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[11]  D. Stern,et al.  Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[13]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Riese,et al.  A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. , 2003, Cancer letters.

[15]  Fu-Chin Liu,et al.  Neural development of the neuregulin receptor ErbB4 in the cerebral cortex and the hippocampus: preferential expression by interneurons tangentially migrating from the ganglionic eminences. , 2003, Cerebral cortex.

[16]  A. Ullrich,et al.  Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.

[17]  G. Carpenter,et al.  ErbB-4: a receptor tyrosine kinase , 2002, Inflammation Research.

[18]  R. Pinkas-Kramarski,et al.  ErbB-4 activation inhibits apoptosis in PC12 cells , 2001, Neuroscience.

[19]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[20]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[21]  P. Kantoff,et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  L. Caskey,et al.  HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells , 2001, Molecular and Cellular Biology.

[23]  J. Smyth,et al.  Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. , 2001, Cancer research.

[24]  Michael J Morin,et al.  From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents , 2000, Oncogene.

[25]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[26]  M. Klagsbrun,et al.  A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis* , 2000, The Journal of Biological Chemistry.

[27]  J. Gibbs.  Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.

[28]  B. Geiger,et al.  Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization , 2000, Oncogene.

[29]  Careen K. Tang,et al.  Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. , 1999, Cancer research.

[30]  P. Kantoff,et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Z. Kam,et al.  Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. , 1998, Molecular biology of the cell.

[32]  Ling-mei Wang,et al.  ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Der,et al.  Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K , 1997, Nature.

[34]  J. Rhim,et al.  ErbB kinases and NDF signaling in human prostate cancer cells , 1997, Oncogene.

[35]  R H Perry,et al.  Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.

[36]  H. Kung,et al.  A tyrosine kinase profile of prostate carcinoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Y. Yarden,et al.  An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*) , 1996, The Journal of Biological Chemistry.

[39]  H. P. Fell,et al.  HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein (*) , 1995, The Journal of Biological Chemistry.

[40]  F. Grigorescu,et al.  Involvement of phosphoinositide 3‐kinase in insulin‐ or IGF‐1‐induced membrane ruffling. , 1994, The EMBO journal.

[41]  P. Stastny,et al.  Macrophage migration from an agarose droplet: development of a micromethod for assay of delayed hypersensitivity. , 1973, Journal of immunology.

[42]  B. Calvo,et al.  The EGF receptor family--multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. , 2003, Transactions of the American Clinical and Climatological Association.

[43]  H. Juhl,et al.  Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. , 2001, International journal of surgical investigation.

[44]  M. Melhem,et al.  Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.